Gene therapy Progress and Prospects: Gene therapy for the hemophilias

Recent gene transfer trials for hemophilia A and B, bleeding disorders lacking either functional factor VIII or IX, respectively, have produced tantalizing results, suggesting that the potential to correct these bleeding disorders at a molecular level may be at hand. Genetic correction of the hemophilias represents a model system to develop a basic understanding of how gene therapy will be achieved. The goals for hemophilia gene transfer require the long-term therapeutic production of the coagulant protein without stimulating an immune response to the transgene product or the vector. Based on a scientific understanding of the molecular and cellular defects, leading to the bleeding phenotype, impressive strides have been made in the last 2 years.

[1]  T. VandenDriessche,et al.  Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.

[2]  C. Slaughter,et al.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.

[3]  M. Kay,et al.  Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system , 2000, Nature Genetics.

[4]  R. Samulski,et al.  AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.

[5]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[6]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[7]  M. Garcia-Blanco,et al.  Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  I. Verma,et al.  Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  M. Poon.  Use of recombinant factor VIIa in hereditary bleeding disorders , 2001, Current opinion in hematology.

[10]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[11]  R. Samulski,et al.  Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  A. Sharpe,et al.  Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .

[13]  B. Brown,et al.  Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. , 2002, Blood.

[14]  D. Treco,et al.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.

[15]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Samulski,et al.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  D. Lillicrap.  Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns. , 2000, Haematologica.

[18]  C. Walsh,et al.  Induction of tolerance to human factor VIII in mice. , 2001, Blood.

[19]  M. Kay,et al.  Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. , 2000, Blood.

[20]  Liming Chang,et al.  Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. , 2002, Blood.

[21]  K. Kurachi,et al.  Bone marrow stromal cells as a genetic platformfor systemic delivery of therapeutic proteins in vivo: human factor IX model , 2003, The journal of gene medicine.